Urothelial carcinoma following augmentation cystoplasty: An aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations

Histopathology

Volumn 55, Issue 2, 2009, Pages 161-173

  Sung, Ming Tse ^a   Zhang, Shaobo ^b   Lopez Beltran, Antonio ^c   Montironi, Rodolfo ^d   Wang, Mingsheng ^b   Davidson, Darrell D ^b   Koch, Michael O ^b   Cain, Mark P ^b   Rink, Richard C ^b   Cheng, Liang ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CÓRDOBA   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Augmentation cystoplasty; Fibroblast growth factor receptor 3; Fluorescence in situ hybridization; Neoplasia; P53 mutation; Urinary bladder

Indexed keywords

BETA CATENIN; CYTOKERATIN 20; CYTOKERATIN 7; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53; TRANSCRIPTION FACTOR CDX2; UROPLAKIN;

ADULT; ARTICLE; BLADDER CARCINOMA; BLADDER NECK; BLADDER RECONSTRUCTION; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CASE REPORT; CHROMOSOME ABERRATION; CONTRACTURE; CONTROLLED STUDY; DISEASE COURSE; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS; MUTATIONAL ANALYSIS; POINT MUTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR NECROSIS; URINARY TRACT INFECTION; UROGENITAL TRACT TUMOR;

ADULT; BETA CATENIN; CARCINOMA, TRANSITIONAL CELL; CELL NUCLEUS; CHROMOSOME ABERRATIONS; CYSTOSCOPY; EXONS; FATAL OUTCOME; FEMALE; GENES, P53; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MITOSIS; NECROSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 68749107464     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03363.x     Document Type: Article

References (55)

1. Mikulicz J. Zur operation der Augeborene blasenspate. Zentralbl. Chir. 1899 26 641.
2. Austen M, Kalble T. Secondary malignancies in different forms of urinary diversion using isolated gut. J. Urol. 2004 172 831 838.
3. Metcalfe PD, Cain MP, Kaefer M et al. What is the need for additional bladder surgery after bladder augmentation in childhood? J. Urol. 2006 176 1801 1805.
4. Soergel TM, Cain MP, Misseri R et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J. Urol. 2004 172 1649 1651.
5. Eble JN, Sauter G, Epstein JI, Sesterhenn I. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon : IARCPress, 2004.
6. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International classification of tumors. Geneva : World Health Organization, 1973.
7. Sung MT, Jiang Z, Montironi R et al. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. Hum. Pathol. 2007 38 332 341.
8. Sung MT, Maclennan GT, Lopez-Beltran A et al. Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases. Am. J. Surg. Pathol. 2008 32 146 155.
9. Sung MT, Zhang S, MacLennan GT et al. Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin. Cancer Res. 2008 14 1947 1955.
10. Bilim V, Kawasaki T, Katagiri A et al. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations. Clin. Cancer Res. 2000 6 460 466.
11. Sung MT, Wang M, MacLennan GT et al. Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J. Pathol. 2007 211 420 430.
12. Kimura T, Suzuki H, Ohashi T et al. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001 92 2555 2561.
13. Bakkar AA, Wallerand H, Radvanyi F et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003 63 8108 8112.
14. Jones TD, Zhang S, Lopez-Beltran A et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am. J. Surg. Pathol. 2007 31 1861 1867.
15. Filmer RB, Spencer JR. Malignancies in bladder augmentations and intestinal conduits. J. Urol. 1990 143 671 678.
16. Shokeir AA, Shamaa M, el-Mekresh MM, el-Baz M, Ghoneim MA. Late malignancy in bowel segments exposed to urine without fecal stream. Urology 1995 46 657 661.
17. Lane T, Shah J. Carcinoma following augmentation ileocystoplasty. Urol. Int. 2000 64 31 32.
18. Golomb J, Klutke CG, Lewin KJ et al. Bladder neoplasms associated with augmentation cystoplasty: report of 2 cases and literature review. J. Urol. 1989 142 377 380.
19. Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum. Pathol. 2006 37 1371 1388.
20. Jozwicki W, Domaniewski J, Skok Z et al. Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study. Urology 2005 66 1122 1126.
21. Wasco MJ, Daignault S, Zhang Y et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 2007 70 69 74.
22. Silberg DG, Sullivan J, Kang E et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002 122 689 696.
23. Ko S, Chu K, Luk JM et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J. Pathol. 2005 205 615 622.
24. Osawa H, Kita H, Satoh K et al. Aberrant expression of CDX2 in the metaplastic epithelium and inflammatory mucosa of the gallbladder. Am. J. Surg. Pathol. 2004 28 1253 1254.
25. Sung MT, Lopez-Beltran A, Eble JN et al. Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod. Pathol. 2006 19 1395 1401.
26. Suh N, Yang XJ, Tretiakova MS, Humphrey PA, Wang HL. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod. Pathol. 2005 18 1217 1222.
27. Behrens J, Vakaet L, Friis R et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature- sensitive v-SRC gene. J. Cell Biol. 1993 120 757 766.
28. Shimazui T, Schalken JA, Giroldi LA et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res. 1996 56 4154 4158.
29. Syrigos KN, Harrington K, Waxman J, Krausz T, Pignatelli M. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J. Urol. 1998 160 1889 1893. (Pubitemid 128746781)
30. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am. J. Pathol. 1995 147 1383 1397.
31. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am. J. Clin. Pathol. 2000 113 683 687.
32. Parker DC, Folpe AL, Bell J et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am. J. Surg. Pathol. 2003 27 1 10.
33. Jiang J, Ulbright TM, Younger C et al. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch. Pathol. Lab. Med. 2001 125 921 923.
34. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM. Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J. Biol. Chem. 1994 269 11620 11627.
35. Passos-Bueno MR, Wilcox WR, Jabs EW et al. Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat. 1999 14 115 125.
36. van Rhijn BW, Vis AN, van der Kwast TH et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 2003 21 1912 1921.
37. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 2002 198 245 251.
38. Fujimoto K, Yamada Y, Okajima E et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res. 1992 52 1393 1398.
39. van Rhijn BW, van der Kwast TH, Vis AN et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004 64 1911 1914.
40. Takahashi T, Habuchi T, Kakehi Y et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 1998 58 5835 5841.
41. Nowell PC. The clonal evolution of tumor cell populations. Science 1976 194 23 28.
42. Orntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol. Res. 1998 26 223 233.
43. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J. Urol. 1994 151 545 560.
44. Meloni AM, Peier AM, Haddad FS et al. A new approach in the diagnosis and follow-up of bladder cancer. FISH analysis of urine, bladder washings, and tumors. Cancer Genet. Cytogenet. 1993 71 105 118.
45. Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol. 2000 164 1768 1775.
46. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 2002 168 1950 1954.
47. Brankley SM, Adams EJ, Christensen MR et al. A study of the reproducibility of a fluorescence in situ hybridization bladder cancer detection assay. Anal. Quant. Cytol. Histol. 2008 30 145 151.
48. Kipp BR, Tyner HL, Campion MB et al. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am. J. Clin. Pathol. 2008 130 552 559.
49. Smith P, Hardy GJ. Carcinoma occurring as a late complication of ileocystoplasty. Br. J. Urol. 1971 43 576 579.
50. Stone AR, Davies N, Stephenson TP. Carcinoma associated with augmentation cystoplasty. Br. J. Urol. 1987 60 236 238.
51. Gregoire M, Kantoff P, DeWolf WC. Synchronous adenocarcinoma and transitional cell carcinoma of the bladder associated with augmentation: case report and review of the literature. J. Urol. 1993 149 115 118.
52. Barrington JW, Fulford S, Griffiths D, Stephenson TP. Tumors in bladder remnant after augmentation enterocystoplasty. J. Urol. 1997 157 482 485.
53. Ali-El-Dein B, El-Tabey N, Abdel-Latif M, Abdel-Rahim M, El-Bahnasawy MS. Late uro-ileal cancer after incorporation of ileum into the urinary tract. J. Urol. 2002 167 84 88.
54. Qiu H, Kordunskaya S, Yantiss RK. Transitional cell carcinoma arising in the gastric remnant following gastrocystoplasty: a case report and review of the literature. Int. J. Surg. Pathol. 2003 11 143 147.
55. Castellan M, Gosalbez R, Perez-Brayfield M et al. Tumor in bladder reservoir after gastrocystoplasty. J. Urol. 2007 178 1771 1774.